nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—PRKCE—coronary artery disease	0.382	0.697	CbGaD
Ruxolitinib—JAK2—coronary artery disease	0.166	0.303	CbGaD
Ruxolitinib—CYP3A4—Ticagrelor—coronary artery disease	0.00638	0.146	CbGbCtD
Ruxolitinib—CYP3A4—Fenofibrate—coronary artery disease	0.00568	0.13	CbGbCtD
Ruxolitinib—BMPR2—pulmonary artery—coronary artery disease	0.00468	0.0586	CbGeAlD
Ruxolitinib—CYP3A4—Gemfibrozil—coronary artery disease	0.00454	0.104	CbGbCtD
Ruxolitinib—CYP3A4—Clopidogrel—coronary artery disease	0.00394	0.0904	CbGbCtD
Ruxolitinib—CYP3A4—Eplerenone—coronary artery disease	0.00366	0.0841	CbGbCtD
Ruxolitinib—CYP3A4—Enalapril—coronary artery disease	0.00326	0.0749	CbGbCtD
Ruxolitinib—CYP3A4—Rosuvastatin—coronary artery disease	0.00254	0.0583	CbGbCtD
Ruxolitinib—CYP3A4—Ezetimibe—coronary artery disease	0.00254	0.0583	CbGbCtD
Ruxolitinib—CYP3A4—Simvastatin—coronary artery disease	0.00236	0.0542	CbGbCtD
Ruxolitinib—RET—autonomic nervous system—coronary artery disease	0.00233	0.0291	CbGeAlD
Ruxolitinib—CYP3A4—Pravastatin—coronary artery disease	0.00231	0.053	CbGbCtD
Ruxolitinib—CYP3A4—Lovastatin—coronary artery disease	0.00231	0.053	CbGbCtD
Ruxolitinib—CYP3A4—Atorvastatin—coronary artery disease	0.0021	0.0483	CbGbCtD
Ruxolitinib—CYP3A4—Losartan—coronary artery disease	0.00192	0.0442	CbGbCtD
Ruxolitinib—BMPR2—artery—coronary artery disease	0.00174	0.0217	CbGeAlD
Ruxolitinib—PRKG2—heart—coronary artery disease	0.00133	0.0166	CbGeAlD
Ruxolitinib—PRKG2—cardiovascular system—coronary artery disease	0.00126	0.0157	CbGeAlD
Ruxolitinib—PRKCE—heart—coronary artery disease	0.00124	0.0155	CbGeAlD
Ruxolitinib—RPS6KA6—heart—coronary artery disease	0.00119	0.0149	CbGeAlD
Ruxolitinib—JAK1—cardiac ventricle—coronary artery disease	0.00116	0.0146	CbGeAlD
Ruxolitinib—RPS6KA6—cardiovascular system—coronary artery disease	0.00113	0.0141	CbGeAlD
Ruxolitinib—DAPK2—cardiac ventricle—coronary artery disease	0.00111	0.0139	CbGeAlD
Ruxolitinib—JAK1—myocardium—coronary artery disease	0.00109	0.0137	CbGeAlD
Ruxolitinib—DAPK2—myocardium—coronary artery disease	0.00104	0.0131	CbGeAlD
Ruxolitinib—DAPK3—cardiac ventricle—coronary artery disease	0.00104	0.0131	CbGeAlD
Ruxolitinib—PLK3—heart—coronary artery disease	0.000996	0.0125	CbGeAlD
Ruxolitinib—DAPK3—myocardium—coronary artery disease	0.000982	0.0123	CbGeAlD
Ruxolitinib—BMPR2—cardiac ventricle—coronary artery disease	0.000974	0.0122	CbGeAlD
Ruxolitinib—PLK3—cardiovascular system—coronary artery disease	0.00094	0.0118	CbGeAlD
Ruxolitinib—CAMK1—heart—coronary artery disease	0.000932	0.0117	CbGeAlD
Ruxolitinib—DYRK1A—myocardium—coronary artery disease	0.00092	0.0115	CbGeAlD
Ruxolitinib—MARK2—heart—coronary artery disease	0.000904	0.0113	CbGeAlD
Ruxolitinib—PLK3—cardiac atrium—coronary artery disease	0.000852	0.0107	CbGeAlD
Ruxolitinib—DCLK3—blood—coronary artery disease	0.000844	0.0106	CbGeAlD
Ruxolitinib—TAOK2—heart—coronary artery disease	0.000837	0.0105	CbGeAlD
Ruxolitinib—MAP3K7—cardiac ventricle—coronary artery disease	0.000784	0.0098	CbGeAlD
Ruxolitinib—TYK2—cardiac ventricle—coronary artery disease	0.00077	0.00963	CbGeAlD
Ruxolitinib—JAK3—heart—coronary artery disease	0.000769	0.00962	CbGeAlD
Ruxolitinib—JAK1—heart—coronary artery disease	0.000764	0.00956	CbGeAlD
Ruxolitinib—DCLK1—heart—coronary artery disease	0.000764	0.00956	CbGeAlD
Ruxolitinib—IRAK1—cardiac ventricle—coronary artery disease	0.00076	0.0095	CbGeAlD
Ruxolitinib—MKNK2—cardiac ventricle—coronary artery disease	0.00076	0.0095	CbGeAlD
Ruxolitinib—CAMK1D—heart—coronary artery disease	0.000746	0.00933	CbGeAlD
Ruxolitinib—PLK3—blood—coronary artery disease	0.000743	0.0093	CbGeAlD
Ruxolitinib—PHKG2—heart—coronary artery disease	0.000742	0.00927	CbGeAlD
Ruxolitinib—MAP3K7—myocardium—coronary artery disease	0.000737	0.00922	CbGeAlD
Ruxolitinib—DAPK2—heart—coronary artery disease	0.000729	0.00912	CbGeAlD
Ruxolitinib—TYK2—myocardium—coronary artery disease	0.000724	0.00905	CbGeAlD
Ruxolitinib—JAK1—cardiovascular system—coronary artery disease	0.000721	0.00902	CbGeAlD
Ruxolitinib—STK16—heart—coronary artery disease	0.000717	0.00897	CbGeAlD
Ruxolitinib—IRAK1—myocardium—coronary artery disease	0.000715	0.00894	CbGeAlD
Ruxolitinib—MKNK2—myocardium—coronary artery disease	0.000715	0.00894	CbGeAlD
Ruxolitinib—HIPK2—heart—coronary artery disease	0.000713	0.00892	CbGeAlD
Ruxolitinib—JAK2—cardiac ventricle—coronary artery disease	0.0007	0.00876	CbGeAlD
Ruxolitinib—CAMK1—blood—coronary artery disease	0.000695	0.00869	CbGeAlD
Ruxolitinib—DAPK3—heart—coronary artery disease	0.000685	0.00857	CbGeAlD
Ruxolitinib—CLK2—heart—coronary artery disease	0.000679	0.00849	CbGeAlD
Ruxolitinib—MARK2—blood—coronary artery disease	0.000675	0.00844	CbGeAlD
Ruxolitinib—MAP3K3—cardiac ventricle—coronary artery disease	0.000675	0.00844	CbGeAlD
Ruxolitinib—HIPK2—cardiovascular system—coronary artery disease	0.000673	0.00842	CbGeAlD
Ruxolitinib—JAK2—myocardium—coronary artery disease	0.000659	0.00824	CbGeAlD
Ruxolitinib—ROCK1—heart—coronary artery disease	0.000658	0.00823	CbGeAlD
Ruxolitinib—JAK1—cardiac atrium—coronary artery disease	0.000654	0.00817	CbGeAlD
Ruxolitinib—DAPK3—cardiovascular system—coronary artery disease	0.000647	0.00809	CbGeAlD
Ruxolitinib—DYRK1A—heart—coronary artery disease	0.000642	0.00803	CbGeAlD
Ruxolitinib—BMPR2—heart—coronary artery disease	0.000639	0.00799	CbGeAlD
Ruxolitinib—CAMK1D—cardiac atrium—coronary artery disease	0.000638	0.00798	CbGeAlD
Ruxolitinib—MAP3K3—myocardium—coronary artery disease	0.000635	0.00794	CbGeAlD
Ruxolitinib—TAOK2—blood—coronary artery disease	0.000624	0.00781	CbGeAlD
Ruxolitinib—DAPK2—cardiac atrium—coronary artery disease	0.000624	0.0078	CbGeAlD
Ruxolitinib—ROCK1—cardiovascular system—coronary artery disease	0.000621	0.00777	CbGeAlD
Ruxolitinib—TAOK3—cardiac ventricle—coronary artery disease	0.000615	0.00769	CbGeAlD
Ruxolitinib—DYRK1A—cardiovascular system—coronary artery disease	0.000606	0.00757	CbGeAlD
Ruxolitinib—BMPR2—cardiovascular system—coronary artery disease	0.000603	0.00754	CbGeAlD
Ruxolitinib—DAPK3—cardiac atrium—coronary artery disease	0.000586	0.00733	CbGeAlD
Ruxolitinib—CLK2—cardiac atrium—coronary artery disease	0.000581	0.00726	CbGeAlD
Ruxolitinib—TAOK3—myocardium—coronary artery disease	0.000579	0.00724	CbGeAlD
Ruxolitinib—JAK3—blood—coronary artery disease	0.000574	0.00718	CbGeAlD
Ruxolitinib—BMP2K—heart—coronary artery disease	0.000572	0.00715	CbGeAlD
Ruxolitinib—CAMK2G—heart—coronary artery disease	0.000572	0.00715	CbGeAlD
Ruxolitinib—JAK1—blood—coronary artery disease	0.00057	0.00713	CbGeAlD
Ruxolitinib—LRRK2—heart—coronary artery disease	0.000567	0.00709	CbGeAlD
Ruxolitinib—PLK4—blood—coronary artery disease	0.000567	0.00709	CbGeAlD
Ruxolitinib—CAMK1D—blood—coronary artery disease	0.000557	0.00696	CbGeAlD
Ruxolitinib—PLK1—Fluvastatin—Pitavastatin—coronary artery disease	0.000552	0.175	CbGdCrCtD
Ruxolitinib—BMPR2—cardiac atrium—coronary artery disease	0.000547	0.00684	CbGeAlD
Ruxolitinib—DAPK2—blood—coronary artery disease	0.000544	0.0068	CbGeAlD
Ruxolitinib—CAMK2G—cardiovascular system—coronary artery disease	0.00054	0.00675	CbGeAlD
Ruxolitinib—STK16—blood—coronary artery disease	0.000535	0.00669	CbGeAlD
Ruxolitinib—MAP3K2—heart—coronary artery disease	0.000519	0.0065	CbGeAlD
Ruxolitinib—MAP3K7—heart—coronary artery disease	0.000515	0.00644	CbGeAlD
Ruxolitinib—DAPK3—blood—coronary artery disease	0.000511	0.0064	CbGeAlD
Ruxolitinib—CLK2—blood—coronary artery disease	0.000507	0.00634	CbGeAlD
Ruxolitinib—TYK2—heart—coronary artery disease	0.000505	0.00632	CbGeAlD
Ruxolitinib—IRAK1—heart—coronary artery disease	0.000499	0.00624	CbGeAlD
Ruxolitinib—MKNK2—heart—coronary artery disease	0.000499	0.00624	CbGeAlD
Ruxolitinib—PLK1—Fluvastatin—Rosuvastatin—coronary artery disease	0.000492	0.156	CbGdCrCtD
Ruxolitinib—ROCK1—blood—coronary artery disease	0.000491	0.00614	CbGeAlD
Ruxolitinib—RET—heart—coronary artery disease	0.000486	0.00608	CbGeAlD
Ruxolitinib—TYK2—cardiovascular system—coronary artery disease	0.000477	0.00596	CbGeAlD
Ruxolitinib—MKNK2—cardiovascular system—coronary artery disease	0.000471	0.00589	CbGeAlD
Ruxolitinib—PLK1—Simvastatin—Lovastatin—coronary artery disease	0.00047	0.15	CbGdCrCtD
Ruxolitinib—PLK1—Simvastatin—Pravastatin—coronary artery disease	0.00047	0.15	CbGdCrCtD
Ruxolitinib—JAK2—heart—coronary artery disease	0.00046	0.00575	CbGeAlD
Ruxolitinib—NUAK2—blood—coronary artery disease	0.000456	0.0057	CbGeAlD
Ruxolitinib—MAP3K3—heart—coronary artery disease	0.000443	0.00554	CbGeAlD
Ruxolitinib—MAP3K7—cardiac atrium—coronary artery disease	0.00044	0.0055	CbGeAlD
Ruxolitinib—JAK2—cardiovascular system—coronary artery disease	0.000434	0.00543	CbGeAlD
Ruxolitinib—TYK2—cardiac atrium—coronary artery disease	0.000432	0.0054	CbGeAlD
Ruxolitinib—CAMK2G—blood—coronary artery disease	0.000427	0.00534	CbGeAlD
Ruxolitinib—BMP2K—blood—coronary artery disease	0.000427	0.00534	CbGeAlD
Ruxolitinib—MKNK2—cardiac atrium—coronary artery disease	0.000427	0.00533	CbGeAlD
Ruxolitinib—LRRK2—blood—coronary artery disease	0.000423	0.00529	CbGeAlD
Ruxolitinib—MAP3K3—cardiovascular system—coronary artery disease	0.000418	0.00523	CbGeAlD
Ruxolitinib—PLK1—Fluvastatin—Atorvastatin—coronary artery disease	0.000418	0.133	CbGdCrCtD
Ruxolitinib—TAOK3—heart—coronary artery disease	0.000404	0.00505	CbGeAlD
Ruxolitinib—PLK1—Pitavastatin—Rosuvastatin—coronary artery disease	0.000401	0.128	CbGdCrCtD
Ruxolitinib—JAK2—cardiac atrium—coronary artery disease	0.000393	0.00492	CbGeAlD
Ruxolitinib—MAP3K2—blood—coronary artery disease	0.000388	0.00485	CbGeAlD
Ruxolitinib—MAP3K7—blood—coronary artery disease	0.000384	0.0048	CbGeAlD
Ruxolitinib—TAOK3—cardiovascular system—coronary artery disease	0.000381	0.00477	CbGeAlD
Ruxolitinib—MAP3K3—cardiac atrium—coronary artery disease	0.000379	0.00474	CbGeAlD
Ruxolitinib—TYK2—blood—coronary artery disease	0.000377	0.00472	CbGeAlD
Ruxolitinib—IRAK1—blood—coronary artery disease	0.000372	0.00465	CbGeAlD
Ruxolitinib—MKNK2—blood—coronary artery disease	0.000372	0.00465	CbGeAlD
Ruxolitinib—RET—blood—coronary artery disease	0.000363	0.00454	CbGeAlD
Ruxolitinib—TAOK3—cardiac atrium—coronary artery disease	0.000345	0.00432	CbGeAlD
Ruxolitinib—JAK2—blood—coronary artery disease	0.000343	0.00429	CbGeAlD
Ruxolitinib—PLK1—Pitavastatin—Atorvastatin—coronary artery disease	0.000341	0.108	CbGdCrCtD
Ruxolitinib—MAP3K3—blood—coronary artery disease	0.000331	0.00414	CbGeAlD
Ruxolitinib—TAOK3—blood—coronary artery disease	0.000301	0.00377	CbGeAlD
Ruxolitinib—Infection—Clopidogrel—coronary artery disease	0.000237	0.00196	CcSEcCtD
Ruxolitinib—Anaemia—Olmesartan—coronary artery disease	0.000236	0.00195	CcSEcCtD
Ruxolitinib—Skin disorder—Fenofibrate—coronary artery disease	0.000235	0.00195	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Eplerenone—coronary artery disease	0.000235	0.00195	CcSEcCtD
Ruxolitinib—Infection—Lovastatin—coronary artery disease	0.000235	0.00195	CcSEcCtD
Ruxolitinib—Flatulence—Trandolapril—coronary artery disease	0.000235	0.00195	CcSEcCtD
Ruxolitinib—Malnutrition—Telmisartan—coronary artery disease	0.000234	0.00194	CcSEcCtD
Ruxolitinib—Flatulence—Enalapril—coronary artery disease	0.000234	0.00194	CcSEcCtD
Ruxolitinib—Nervous system disorder—Clopidogrel—coronary artery disease	0.000234	0.00194	CcSEcCtD
Ruxolitinib—Headache—Penbutolol—coronary artery disease	0.000233	0.00193	CcSEcCtD
Ruxolitinib—Weight increased—Ramipril—coronary artery disease	0.000232	0.00192	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Lovastatin—coronary artery disease	0.000232	0.00192	CcSEcCtD
Ruxolitinib—Skin disorder—Clopidogrel—coronary artery disease	0.000231	0.00192	CcSEcCtD
Ruxolitinib—Infection—Ezetimibe—coronary artery disease	0.000231	0.00191	CcSEcCtD
Ruxolitinib—Flatulence—Telmisartan—coronary artery disease	0.00023	0.00191	CcSEcCtD
Ruxolitinib—Asthenia—Gemfibrozil—coronary artery disease	0.000228	0.00189	CcSEcCtD
Ruxolitinib—Nervous system disorder—Ezetimibe—coronary artery disease	0.000228	0.00189	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Ezetimibe—coronary artery disease	0.000227	0.00188	CcSEcCtD
Ruxolitinib—Anaemia—Pravastatin—coronary artery disease	0.000227	0.00188	CcSEcCtD
Ruxolitinib—Infection—Eplerenone—coronary artery disease	0.000226	0.00187	CcSEcCtD
Ruxolitinib—Weight decreased—Timolol—coronary artery disease	0.000225	0.00187	CcSEcCtD
Ruxolitinib—Skin disorder—Ezetimibe—coronary artery disease	0.000225	0.00187	CcSEcCtD
Ruxolitinib—Pruritus—Gemfibrozil—coronary artery disease	0.000225	0.00186	CcSEcCtD
Ruxolitinib—Nervous system disorder—Eplerenone—coronary artery disease	0.000223	0.00185	CcSEcCtD
Ruxolitinib—Asthenia—Ticagrelor—coronary artery disease	0.000223	0.00185	CcSEcCtD
Ruxolitinib—Urinary tract infection—Ramipril—coronary artery disease	0.000221	0.00183	CcSEcCtD
Ruxolitinib—Malnutrition—Perindopril—coronary artery disease	0.000221	0.00183	CcSEcCtD
Ruxolitinib—Skin disorder—Eplerenone—coronary artery disease	0.000221	0.00183	CcSEcCtD
Ruxolitinib—Anaemia—Trandolapril—coronary artery disease	0.00022	0.00182	CcSEcCtD
Ruxolitinib—Infection—Simvastatin—coronary artery disease	0.00022	0.00182	CcSEcCtD
Ruxolitinib—Pancytopenia—Lisinopril—coronary artery disease	0.00022	0.00182	CcSEcCtD
Ruxolitinib—Pruritus—Ticagrelor—coronary artery disease	0.000219	0.00182	CcSEcCtD
Ruxolitinib—Anaemia—Enalapril—coronary artery disease	0.000219	0.00182	CcSEcCtD
Ruxolitinib—Flatulence—Perindopril—coronary artery disease	0.000218	0.0018	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Simvastatin—coronary artery disease	0.000217	0.0018	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Valsartan—coronary artery disease	0.000217	0.0018	CcSEcCtD
Ruxolitinib—Anaemia—Telmisartan—coronary artery disease	0.000216	0.00179	CcSEcCtD
Ruxolitinib—Neutropenia—Lisinopril—coronary artery disease	0.000216	0.00179	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Olmesartan—coronary artery disease	0.000216	0.00179	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Ramipril—coronary artery disease	0.000215	0.00178	CcSEcCtD
Ruxolitinib—Malnutrition—Furosemide—coronary artery disease	0.000215	0.00178	CcSEcCtD
Ruxolitinib—Epistaxis—Ramipril—coronary artery disease	0.000214	0.00178	CcSEcCtD
Ruxolitinib—Flatulence—Furosemide—coronary artery disease	0.000212	0.00175	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Niacin—coronary artery disease	0.000211	0.00175	CcSEcCtD
Ruxolitinib—Weight increased—Lisinopril—coronary artery disease	0.00021	0.00174	CcSEcCtD
Ruxolitinib—Anaemia—Captopril—coronary artery disease	0.00021	0.00174	CcSEcCtD
Ruxolitinib—Dizziness—Gemfibrozil—coronary artery disease	0.00021	0.00174	CcSEcCtD
Ruxolitinib—Epistaxis—Timolol—coronary artery disease	0.00021	0.00174	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Fenofibrate—coronary artery disease	0.000209	0.00173	CcSEcCtD
Ruxolitinib—Weight decreased—Lisinopril—coronary artery disease	0.000209	0.00173	CcSEcCtD
Ruxolitinib—Fatigue—Fenofibrate—coronary artery disease	0.000209	0.00173	CcSEcCtD
Ruxolitinib—Infection—Valsartan—coronary artery disease	0.000208	0.00172	CcSEcCtD
Ruxolitinib—Infection—Olmesartan—coronary artery disease	0.000207	0.00171	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Clopidogrel—coronary artery disease	0.000206	0.0017	CcSEcCtD
Ruxolitinib—Fatigue—Clopidogrel—coronary artery disease	0.000205	0.0017	CcSEcCtD
Ruxolitinib—Dizziness—Ticagrelor—coronary artery disease	0.000205	0.0017	CcSEcCtD
Ruxolitinib—Nervous system disorder—Valsartan—coronary artery disease	0.000205	0.0017	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Valsartan—coronary artery disease	0.000205	0.0017	CcSEcCtD
Ruxolitinib—Anaemia—Perindopril—coronary artery disease	0.000204	0.00169	CcSEcCtD
Ruxolitinib—Flatulence—Losartan—coronary artery disease	0.000204	0.00169	CcSEcCtD
Ruxolitinib—Fatigue—Lovastatin—coronary artery disease	0.000204	0.00169	CcSEcCtD
Ruxolitinib—Nervous system disorder—Olmesartan—coronary artery disease	0.000204	0.00169	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Olmesartan—coronary artery disease	0.000204	0.00169	CcSEcCtD
Ruxolitinib—Skin disorder—Valsartan—coronary artery disease	0.000203	0.00168	CcSEcCtD
Ruxolitinib—Skin disorder—Olmesartan—coronary artery disease	0.000202	0.00168	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Trandolapril—coronary artery disease	0.000201	0.00167	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Ezetimibe—coronary artery disease	0.0002	0.00166	CcSEcCtD
Ruxolitinib—Urinary tract infection—Lisinopril—coronary artery disease	0.0002	0.00166	CcSEcCtD
Ruxolitinib—Asthenia—Rosuvastatin—coronary artery disease	0.0002	0.00166	CcSEcCtD
Ruxolitinib—Fatigue—Ezetimibe—coronary artery disease	0.0002	0.00166	CcSEcCtD
Ruxolitinib—Headache—Gemfibrozil—coronary artery disease	0.000199	0.00165	CcSEcCtD
Ruxolitinib—Infection—Pravastatin—coronary artery disease	0.000199	0.00165	CcSEcCtD
Ruxolitinib—Anaemia—Furosemide—coronary artery disease	0.000198	0.00164	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Telmisartan—coronary artery disease	0.000198	0.00164	CcSEcCtD
Ruxolitinib—Pruritus—Rosuvastatin—coronary artery disease	0.000198	0.00164	CcSEcCtD
Ruxolitinib—Skin disorder—Niacin—coronary artery disease	0.000197	0.00164	CcSEcCtD
Ruxolitinib—Haematuria—Lisinopril—coronary artery disease	0.000197	0.00163	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Eplerenone—coronary artery disease	0.000196	0.00163	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Pravastatin—coronary artery disease	0.000196	0.00162	CcSEcCtD
Ruxolitinib—Fatigue—Eplerenone—coronary artery disease	0.000196	0.00162	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Lisinopril—coronary artery disease	0.000195	0.00162	CcSEcCtD
Ruxolitinib—Epistaxis—Lisinopril—coronary artery disease	0.000194	0.00161	CcSEcCtD
Ruxolitinib—Headache—Ticagrelor—coronary artery disease	0.000194	0.00161	CcSEcCtD
Ruxolitinib—Infection—Trandolapril—coronary artery disease	0.000193	0.0016	CcSEcCtD
Ruxolitinib—Pruritus—Acetylsalicylic acid—coronary artery disease	0.000192	0.00159	CcSEcCtD
Ruxolitinib—Body temperature increased—Fenofibrate—coronary artery disease	0.000192	0.00159	CcSEcCtD
Ruxolitinib—Anaemia—Losartan—coronary artery disease	0.000191	0.00159	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Simvastatin—coronary artery disease	0.000191	0.00158	CcSEcCtD
Ruxolitinib—Fatigue—Simvastatin—coronary artery disease	0.000191	0.00158	CcSEcCtD
Ruxolitinib—Nervous system disorder—Trandolapril—coronary artery disease	0.000191	0.00158	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Trandolapril—coronary artery disease	0.00019	0.00158	CcSEcCtD
Ruxolitinib—Infection—Telmisartan—coronary artery disease	0.00019	0.00157	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Enalapril—coronary artery disease	0.00019	0.00157	CcSEcCtD
Ruxolitinib—Skin disorder—Trandolapril—coronary artery disease	0.000189	0.00156	CcSEcCtD
Ruxolitinib—Body temperature increased—Clopidogrel—coronary artery disease	0.000188	0.00156	CcSEcCtD
Ruxolitinib—Nervous system disorder—Telmisartan—coronary artery disease	0.000187	0.00155	CcSEcCtD
Ruxolitinib—Body temperature increased—Lovastatin—coronary artery disease	0.000187	0.00155	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Telmisartan—coronary artery disease	0.000187	0.00155	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Perindopril—coronary artery disease	0.000187	0.00155	CcSEcCtD
Ruxolitinib—Skin disorder—Telmisartan—coronary artery disease	0.000185	0.00154	CcSEcCtD
Ruxolitinib—Dizziness—Rosuvastatin—coronary artery disease	0.000185	0.00153	CcSEcCtD
Ruxolitinib—Body temperature increased—Ezetimibe—coronary artery disease	0.000183	0.00152	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Captopril—coronary artery disease	0.000182	0.00151	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Furosemide—coronary artery disease	0.000182	0.0015	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Valsartan—coronary artery disease	0.00018	0.0015	CcSEcCtD
Ruxolitinib—Fatigue—Valsartan—coronary artery disease	0.00018	0.00149	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Olmesartan—coronary artery disease	0.00018	0.00149	CcSEcCtD
Ruxolitinib—Body temperature increased—Eplerenone—coronary artery disease	0.00018	0.00149	CcSEcCtD
Ruxolitinib—Dizziness—Acetylsalicylic acid—coronary artery disease	0.000179	0.00149	CcSEcCtD
Ruxolitinib—Fatigue—Olmesartan—coronary artery disease	0.000179	0.00149	CcSEcCtD
Ruxolitinib—Malnutrition—Ramipril—coronary artery disease	0.000178	0.00147	CcSEcCtD
Ruxolitinib—Nervous system disorder—Perindopril—coronary artery disease	0.000177	0.00147	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Perindopril—coronary artery disease	0.000176	0.00146	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Niacin—coronary artery disease	0.000175	0.00145	CcSEcCtD
Ruxolitinib—Skin disorder—Perindopril—coronary artery disease	0.000175	0.00145	CcSEcCtD
Ruxolitinib—Body temperature increased—Simvastatin—coronary artery disease	0.000175	0.00145	CcSEcCtD
Ruxolitinib—Headache—Rosuvastatin—coronary artery disease	0.000175	0.00145	CcSEcCtD
Ruxolitinib—Asthenia—Fenofibrate—coronary artery disease	0.000174	0.00144	CcSEcCtD
Ruxolitinib—Malnutrition—Timolol—coronary artery disease	0.000174	0.00144	CcSEcCtD
Ruxolitinib—Fatigue—Pravastatin—coronary artery disease	0.000173	0.00143	CcSEcCtD
Ruxolitinib—Nervous system disorder—Furosemide—coronary artery disease	0.000172	0.00142	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Furosemide—coronary artery disease	0.000172	0.00142	CcSEcCtD
Ruxolitinib—Pruritus—Fenofibrate—coronary artery disease	0.000171	0.00142	CcSEcCtD
Ruxolitinib—Asthenia—Clopidogrel—coronary artery disease	0.000171	0.00142	CcSEcCtD
Ruxolitinib—Skin disorder—Furosemide—coronary artery disease	0.00017	0.00141	CcSEcCtD
Ruxolitinib—Asthenia—Lovastatin—coronary artery disease	0.00017	0.00141	CcSEcCtD
Ruxolitinib—Pruritus—Clopidogrel—coronary artery disease	0.000169	0.0014	CcSEcCtD
Ruxolitinib—Infection—Losartan—coronary artery disease	0.000168	0.00139	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Trandolapril—coronary artery disease	0.000168	0.00139	CcSEcCtD
Ruxolitinib—Fatigue—Trandolapril—coronary artery disease	0.000168	0.00139	CcSEcCtD
Ruxolitinib—Pruritus—Lovastatin—coronary artery disease	0.000167	0.00139	CcSEcCtD
Ruxolitinib—Fatigue—Enalapril—coronary artery disease	0.000167	0.00138	CcSEcCtD
Ruxolitinib—Asthenia—Ezetimibe—coronary artery disease	0.000167	0.00138	CcSEcCtD
Ruxolitinib—Nervous system disorder—Losartan—coronary artery disease	0.000166	0.00137	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Losartan—coronary artery disease	0.000166	0.00137	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Telmisartan—coronary artery disease	0.000165	0.00137	CcSEcCtD
Ruxolitinib—Fatigue—Telmisartan—coronary artery disease	0.000165	0.00136	CcSEcCtD
Ruxolitinib—Body temperature increased—Olmesartan—coronary artery disease	0.000164	0.00136	CcSEcCtD
Ruxolitinib—Pruritus—Ezetimibe—coronary artery disease	0.000164	0.00136	CcSEcCtD
Ruxolitinib—Asthenia—Eplerenone—coronary artery disease	0.000163	0.00135	CcSEcCtD
Ruxolitinib—Malnutrition—Lisinopril—coronary artery disease	0.000161	0.00134	CcSEcCtD
Ruxolitinib—Pruritus—Eplerenone—coronary artery disease	0.000161	0.00133	CcSEcCtD
Ruxolitinib—Body temperature increased—Niacin—coronary artery disease	0.000161	0.00133	CcSEcCtD
Ruxolitinib—Dizziness—Fenofibrate—coronary artery disease	0.00016	0.00133	CcSEcCtD
Ruxolitinib—Fatigue—Captopril—coronary artery disease	0.00016	0.00133	CcSEcCtD
Ruxolitinib—Asthenia—Simvastatin—coronary artery disease	0.000159	0.00132	CcSEcCtD
Ruxolitinib—Flatulence—Lisinopril—coronary artery disease	0.000159	0.00132	CcSEcCtD
Ruxolitinib—Body temperature increased—Pravastatin—coronary artery disease	0.000158	0.00131	CcSEcCtD
Ruxolitinib—Dizziness—Clopidogrel—coronary artery disease	0.000158	0.00131	CcSEcCtD
Ruxolitinib—Pruritus—Simvastatin—coronary artery disease	0.000157	0.0013	CcSEcCtD
Ruxolitinib—Dizziness—Lovastatin—coronary artery disease	0.000156	0.0013	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Perindopril—coronary artery disease	0.000156	0.00129	CcSEcCtD
Ruxolitinib—Fatigue—Perindopril—coronary artery disease	0.000155	0.00129	CcSEcCtD
Ruxolitinib—Body temperature increased—Trandolapril—coronary artery disease	0.000154	0.00127	CcSEcCtD
Ruxolitinib—Dizziness—Ezetimibe—coronary artery disease	0.000153	0.00127	CcSEcCtD
Ruxolitinib—Body temperature increased—Enalapril—coronary artery disease	0.000153	0.00127	CcSEcCtD
Ruxolitinib—Headache—Fenofibrate—coronary artery disease	0.000152	0.00126	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Furosemide—coronary artery disease	0.000151	0.00125	CcSEcCtD
Ruxolitinib—Fatigue—Furosemide—coronary artery disease	0.000151	0.00125	CcSEcCtD
Ruxolitinib—Body temperature increased—Telmisartan—coronary artery disease	0.000151	0.00125	CcSEcCtD
Ruxolitinib—Dizziness—Eplerenone—coronary artery disease	0.00015	0.00125	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—coronary artery disease	0.00015	0.00124	CcSEcCtD
Ruxolitinib—Asthenia—Valsartan—coronary artery disease	0.00015	0.00124	CcSEcCtD
Ruxolitinib—Asthenia—Olmesartan—coronary artery disease	0.000149	0.00124	CcSEcCtD
Ruxolitinib—Headache—Clopidogrel—coronary artery disease	0.000149	0.00124	CcSEcCtD
Ruxolitinib—Anaemia—Lisinopril—coronary artery disease	0.000149	0.00123	CcSEcCtD
Ruxolitinib—Headache—Lovastatin—coronary artery disease	0.000148	0.00123	CcSEcCtD
Ruxolitinib—Pruritus—Valsartan—coronary artery disease	0.000148	0.00123	CcSEcCtD
Ruxolitinib—Pruritus—Olmesartan—coronary artery disease	0.000147	0.00122	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Timolol—coronary artery disease	0.000147	0.00122	CcSEcCtD
Ruxolitinib—Body temperature increased—Captopril—coronary artery disease	0.000147	0.00122	CcSEcCtD
Ruxolitinib—Dizziness—Simvastatin—coronary artery disease	0.000146	0.00121	CcSEcCtD
Ruxolitinib—Asthenia—Niacin—coronary artery disease	0.000146	0.00121	CcSEcCtD
Ruxolitinib—Fatigue—Losartan—coronary artery disease	0.000146	0.00121	CcSEcCtD
Ruxolitinib—Headache—Ezetimibe—coronary artery disease	0.000145	0.00121	CcSEcCtD
Ruxolitinib—Pruritus—Niacin—coronary artery disease	0.000144	0.00119	CcSEcCtD
Ruxolitinib—Asthenia—Pravastatin—coronary artery disease	0.000144	0.00119	CcSEcCtD
Ruxolitinib—Body temperature increased—Perindopril—coronary artery disease	0.000142	0.00118	CcSEcCtD
Ruxolitinib—Headache—Eplerenone—coronary artery disease	0.000142	0.00118	CcSEcCtD
Ruxolitinib—Nervous system disorder—Ramipril—coronary artery disease	0.000142	0.00118	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Ramipril—coronary artery disease	0.000142	0.00118	CcSEcCtD
Ruxolitinib—Pruritus—Pravastatin—coronary artery disease	0.000142	0.00117	CcSEcCtD
Ruxolitinib—Skin disorder—Ramipril—coronary artery disease	0.000141	0.00117	CcSEcCtD
Ruxolitinib—Infection—Timolol—coronary artery disease	0.000141	0.00117	CcSEcCtD
Ruxolitinib—Asthenia—Trandolapril—coronary artery disease	0.000139	0.00116	CcSEcCtD
Ruxolitinib—Nervous system disorder—Timolol—coronary artery disease	0.000139	0.00115	CcSEcCtD
Ruxolitinib—Asthenia—Enalapril—coronary artery disease	0.000139	0.00115	CcSEcCtD
Ruxolitinib—Headache—Simvastatin—coronary artery disease	0.000139	0.00115	CcSEcCtD
Ruxolitinib—Body temperature increased—Furosemide—coronary artery disease	0.000139	0.00115	CcSEcCtD
Ruxolitinib—Dizziness—Valsartan—coronary artery disease	0.000138	0.00115	CcSEcCtD
Ruxolitinib—Skin disorder—Timolol—coronary artery disease	0.000138	0.00114	CcSEcCtD
Ruxolitinib—Dizziness—Olmesartan—coronary artery disease	0.000138	0.00114	CcSEcCtD
Ruxolitinib—Pruritus—Trandolapril—coronary artery disease	0.000137	0.00114	CcSEcCtD
Ruxolitinib—Asthenia—Telmisartan—coronary artery disease	0.000137	0.00114	CcSEcCtD
Ruxolitinib—Pruritus—Enalapril—coronary artery disease	0.000137	0.00114	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—coronary artery disease	0.000136	0.00113	CcSEcCtD
Ruxolitinib—Pruritus—Telmisartan—coronary artery disease	0.000135	0.00112	CcSEcCtD
Ruxolitinib—Dizziness—Niacin—coronary artery disease	0.000134	0.00111	CcSEcCtD
Ruxolitinib—Body temperature increased—Losartan—coronary artery disease	0.000134	0.00111	CcSEcCtD
Ruxolitinib—Asthenia—Captopril—coronary artery disease	0.000133	0.0011	CcSEcCtD
Ruxolitinib—Dizziness—Pravastatin—coronary artery disease	0.000132	0.0011	CcSEcCtD
Ruxolitinib—Pruritus—Captopril—coronary artery disease	0.000131	0.00109	CcSEcCtD
Ruxolitinib—Headache—Valsartan—coronary artery disease	0.000131	0.00109	CcSEcCtD
Ruxolitinib—Infection—Lisinopril—coronary artery disease	0.000131	0.00108	CcSEcCtD
Ruxolitinib—Headache—Olmesartan—coronary artery disease	0.00013	0.00108	CcSEcCtD
Ruxolitinib—Asthenia—Perindopril—coronary artery disease	0.000129	0.00107	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Lisinopril—coronary artery disease	0.000129	0.00107	CcSEcCtD
Ruxolitinib—Dizziness—Trandolapril—coronary artery disease	0.000129	0.00107	CcSEcCtD
Ruxolitinib—Dizziness—Enalapril—coronary artery disease	0.000128	0.00106	CcSEcCtD
Ruxolitinib—Skin disorder—Lisinopril—coronary artery disease	0.000128	0.00106	CcSEcCtD
Ruxolitinib—Pruritus—Perindopril—coronary artery disease	0.000128	0.00106	CcSEcCtD
Ruxolitinib—Headache—Niacin—coronary artery disease	0.000127	0.00106	CcSEcCtD
Ruxolitinib—Dizziness—Telmisartan—coronary artery disease	0.000126	0.00105	CcSEcCtD
Ruxolitinib—Asthenia—Furosemide—coronary artery disease	0.000126	0.00104	CcSEcCtD
Ruxolitinib—Headache—Pravastatin—coronary artery disease	0.000125	0.00104	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Ramipril—coronary artery disease	0.000125	0.00104	CcSEcCtD
Ruxolitinib—Fatigue—Ramipril—coronary artery disease	0.000125	0.00104	CcSEcCtD
Ruxolitinib—Pruritus—Furosemide—coronary artery disease	0.000124	0.00103	CcSEcCtD
Ruxolitinib—Dizziness—Captopril—coronary artery disease	0.000123	0.00102	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Timolol—coronary artery disease	0.000122	0.00101	CcSEcCtD
Ruxolitinib—Fatigue—Timolol—coronary artery disease	0.000122	0.00101	CcSEcCtD
Ruxolitinib—Headache—Trandolapril—coronary artery disease	0.000122	0.00101	CcSEcCtD
Ruxolitinib—Asthenia—Losartan—coronary artery disease	0.000121	0.00101	CcSEcCtD
Ruxolitinib—Headache—Enalapril—coronary artery disease	0.000121	0.00101	CcSEcCtD
Ruxolitinib—Pruritus—Losartan—coronary artery disease	0.00012	0.000992	CcSEcCtD
Ruxolitinib—Headache—Telmisartan—coronary artery disease	0.00012	0.000991	CcSEcCtD
Ruxolitinib—Dizziness—Perindopril—coronary artery disease	0.000119	0.000988	CcSEcCtD
Ruxolitinib—Headache—Captopril—coronary artery disease	0.000116	0.000964	CcSEcCtD
Ruxolitinib—Dizziness—Furosemide—coronary artery disease	0.000116	0.00096	CcSEcCtD
Ruxolitinib—Body temperature increased—Ramipril—coronary artery disease	0.000115	0.00095	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Lisinopril—coronary artery disease	0.000114	0.000941	CcSEcCtD
Ruxolitinib—Fatigue—Lisinopril—coronary artery disease	0.000113	0.00094	CcSEcCtD
Ruxolitinib—Headache—Perindopril—coronary artery disease	0.000113	0.000936	CcSEcCtD
Ruxolitinib—Body temperature increased—Timolol—coronary artery disease	0.000112	0.000929	CcSEcCtD
Ruxolitinib—Dizziness—Losartan—coronary artery disease	0.000112	0.000927	CcSEcCtD
Ruxolitinib—Headache—Furosemide—coronary artery disease	0.00011	0.00091	CcSEcCtD
Ruxolitinib—Headache—Losartan—coronary artery disease	0.000106	0.000878	CcSEcCtD
Ruxolitinib—Asthenia—Ramipril—coronary artery disease	0.000104	0.000862	CcSEcCtD
Ruxolitinib—Body temperature increased—Lisinopril—coronary artery disease	0.000104	0.000862	CcSEcCtD
Ruxolitinib—Pruritus—Ramipril—coronary artery disease	0.000103	0.00085	CcSEcCtD
Ruxolitinib—Asthenia—Timolol—coronary artery disease	0.000102	0.000843	CcSEcCtD
Ruxolitinib—Pruritus—Timolol—coronary artery disease	0.0001	0.000831	CcSEcCtD
Ruxolitinib—Dizziness—Ramipril—coronary artery disease	9.59e-05	0.000795	CcSEcCtD
Ruxolitinib—Asthenia—Lisinopril—coronary artery disease	9.43e-05	0.000782	CcSEcCtD
Ruxolitinib—Dizziness—Timolol—coronary artery disease	9.37e-05	0.000777	CcSEcCtD
Ruxolitinib—Pruritus—Lisinopril—coronary artery disease	9.3e-05	0.000771	CcSEcCtD
Ruxolitinib—CYP3A4—blood—coronary artery disease	9.16e-05	0.00115	CbGeAlD
Ruxolitinib—Headache—Ramipril—coronary artery disease	9.08e-05	0.000753	CcSEcCtD
Ruxolitinib—Headache—Timolol—coronary artery disease	8.88e-05	0.000736	CcSEcCtD
Ruxolitinib—Dizziness—Lisinopril—coronary artery disease	8.69e-05	0.000721	CcSEcCtD
Ruxolitinib—Headache—Lisinopril—coronary artery disease	8.24e-05	0.000683	CcSEcCtD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—coronary artery disease	9.35e-07	4.58e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—POMC—coronary artery disease	9.33e-07	4.57e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CREB1—coronary artery disease	9.33e-07	4.57e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—IL6—coronary artery disease	9.29e-07	4.55e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—GPCR downstream signaling—AKT1—coronary artery disease	9.29e-07	4.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—CXCL8—coronary artery disease	9.26e-07	4.53e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—AKT1—coronary artery disease	9.25e-07	4.53e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IGF1—coronary artery disease	9.24e-07	4.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—IL6—coronary artery disease	9.24e-07	4.52e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—VEGFA—coronary artery disease	9.23e-07	4.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SERPINE1—coronary artery disease	9.22e-07	4.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—PIK3CA—coronary artery disease	9.21e-07	4.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PPP2CA—coronary artery disease	9.21e-07	4.51e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—coronary artery disease	9.2e-07	4.5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—BCL2—coronary artery disease	9.18e-07	4.49e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—IL6—coronary artery disease	9.14e-07	4.47e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCL2—coronary artery disease	9.13e-07	4.47e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—GSK3B—coronary artery disease	9.12e-07	4.46e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—AKT1—coronary artery disease	9.11e-07	4.46e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CCND1—coronary artery disease	9.11e-07	4.46e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6R—coronary artery disease	9.1e-07	4.45e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—POMC—coronary artery disease	9.05e-07	4.43e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CREB1—coronary artery disease	9.05e-07	4.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PRKCD—coronary artery disease	9.04e-07	4.43e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HK2—coronary artery disease	9.03e-07	4.42e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1B1—coronary artery disease	9.03e-07	4.42e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IGF1—coronary artery disease	8.97e-07	4.39e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CCND1—coronary artery disease	8.96e-07	4.38e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—MAPK1—coronary artery disease	8.93e-07	4.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FGF2—coronary artery disease	8.93e-07	4.37e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—PIK3CA—coronary artery disease	8.85e-07	4.33e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCL2—coronary artery disease	8.85e-07	4.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HTR2A—coronary artery disease	8.85e-07	4.33e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MMP9—coronary artery disease	8.84e-07	4.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—C3—coronary artery disease	8.84e-07	4.33e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6R—coronary artery disease	8.82e-07	4.32e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOS3—coronary artery disease	8.8e-07	4.31e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SERPINE1—coronary artery disease	8.78e-07	4.3e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IGF1—coronary artery disease	8.7e-07	4.26e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MMP9—coronary artery disease	8.69e-07	4.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC27A1—coronary artery disease	8.66e-07	4.24e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—AKT1—coronary artery disease	8.57e-07	4.2e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—PIK3CA—coronary artery disease	8.54e-07	4.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—AKT1—coronary artery disease	8.52e-07	4.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SERPINE1—coronary artery disease	8.52e-07	4.17e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FGF2—coronary artery disease	8.5e-07	4.16e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—IL6—coronary artery disease	8.49e-07	4.16e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LCAT—coronary artery disease	8.49e-07	4.16e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CPT1B—coronary artery disease	8.49e-07	4.16e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TGFB1—coronary artery disease	8.47e-07	4.15e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—AKT1—coronary artery disease	8.43e-07	4.13e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HIF1A—coronary artery disease	8.43e-07	4.13e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MAPK1—coronary artery disease	8.4e-07	4.11e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AGT—coronary artery disease	8.4e-07	4.11e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOS3—coronary artery disease	8.38e-07	4.1e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—AKT1—coronary artery disease	8.36e-07	4.09e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA4—coronary artery disease	8.33e-07	4.08e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MAPK1—coronary artery disease	8.31e-07	4.07e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SERPINE1—coronary artery disease	8.26e-07	4.04e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FGF2—coronary artery disease	8.25e-07	4.04e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOE—coronary artery disease	8.23e-07	4.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—LEP—coronary artery disease	8.23e-07	4.03e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MAPK1—coronary artery disease	8.16e-07	3.99e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—IL6—coronary artery disease	8.16e-07	3.99e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JAK2—coronary artery disease	8.14e-07	3.99e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APOA1—coronary artery disease	8.13e-07	3.98e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOS3—coronary artery disease	8.13e-07	3.98e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL1B—coronary artery disease	8.11e-07	3.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KDR—coronary artery disease	8.06e-07	3.95e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTGS2—coronary artery disease	8.05e-07	3.94e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PDHA1—coronary artery disease	8.05e-07	3.94e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCLM—coronary artery disease	8.05e-07	3.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK14—coronary artery disease	8.01e-07	3.92e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGF2—coronary artery disease	8e-07	3.92e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—VEGFA—coronary artery disease	7.94e-07	3.89e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MAPK1—coronary artery disease	7.91e-07	3.87e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JAK2—coronary artery disease	7.91e-07	3.87e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOS3—coronary artery disease	7.89e-07	3.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ESR1—coronary artery disease	7.86e-07	3.85e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—IL6—coronary artery disease	7.84e-07	3.84e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—coronary artery disease	7.83e-07	3.83e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—coronary artery disease	7.81e-07	3.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TXNRD1—coronary artery disease	7.8e-07	3.82e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP11B2—coronary artery disease	7.8e-07	3.82e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—F2—coronary artery disease	7.76e-07	3.8e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FN1—coronary artery disease	7.76e-07	3.8e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—coronary artery disease	7.75e-07	3.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6ST—coronary artery disease	7.73e-07	3.78e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TGFB1—coronary artery disease	7.68e-07	3.76e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC22A3—coronary artery disease	7.68e-07	3.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NFKBIA—coronary artery disease	7.67e-07	3.75e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JAK2—coronary artery disease	7.67e-07	3.75e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ARNTL—coronary artery disease	7.57e-07	3.7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HADH—coronary artery disease	7.57e-07	3.7e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—coronary artery disease	7.56e-07	3.7e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MAPK1—coronary artery disease	7.53e-07	3.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—coronary artery disease	7.52e-07	3.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—coronary artery disease	7.43e-07	3.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIT—coronary artery disease	7.43e-07	3.63e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—coronary artery disease	7.29e-07	3.57e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TGFB1—coronary artery disease	7.29e-07	3.57e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—coronary artery disease	7.23e-07	3.54e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—coronary artery disease	7.22e-07	3.53e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—coronary artery disease	7.21e-07	3.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA2—coronary artery disease	7.17e-07	3.51e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX2—coronary artery disease	7.17e-07	3.51e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G2A—coronary artery disease	7.17e-07	3.51e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TGFB1—coronary artery disease	7.17e-07	3.51e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK1—coronary artery disease	7.14e-07	3.5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—GSK3B—coronary artery disease	7.13e-07	3.49e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—coronary artery disease	7.11e-07	3.48e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SULT1A1—coronary artery disease	7.09e-07	3.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX4—coronary artery disease	7.09e-07	3.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCG5—coronary artery disease	7.09e-07	3.47e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HK1—coronary artery disease	7.09e-07	3.47e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—coronary artery disease	7.08e-07	3.47e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CREB1—coronary artery disease	7.07e-07	3.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—POMC—coronary artery disease	7.07e-07	3.46e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK1—coronary artery disease	7.03e-07	3.44e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HADHA—coronary artery disease	7e-07	3.43e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—coronary artery disease	7e-07	3.43e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—coronary artery disease	6.98e-07	3.41e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—coronary artery disease	6.92e-07	3.39e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA1—coronary artery disease	6.92e-07	3.39e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCL2—coronary artery disease	6.92e-07	3.39e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—coronary artery disease	6.91e-07	3.38e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6R—coronary artery disease	6.9e-07	3.38e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—coronary artery disease	6.87e-07	3.36e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—coronary artery disease	6.86e-07	3.36e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPA—coronary artery disease	6.84e-07	3.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IGF1—coronary artery disease	6.8e-07	3.33e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK1—coronary artery disease	6.77e-07	3.31e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—coronary artery disease	6.72e-07	3.29e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—coronary artery disease	6.72e-07	3.29e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—coronary artery disease	6.7e-07	3.28e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLCB3—coronary artery disease	6.63e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA5—coronary artery disease	6.56e-07	3.21e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—coronary artery disease	6.54e-07	3.2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—coronary artery disease	6.53e-07	3.19e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—coronary artery disease	6.52e-07	3.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—coronary artery disease	6.47e-07	3.17e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—coronary artery disease	6.46e-07	3.16e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SERPINE1—coronary artery disease	6.46e-07	3.16e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—P4HB—coronary artery disease	6.44e-07	3.15e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—coronary artery disease	6.38e-07	3.12e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—coronary artery disease	6.33e-07	3.1e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—coronary artery disease	6.33e-07	3.1e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLA2G1B—coronary artery disease	6.32e-07	3.09e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—coronary artery disease	6.27e-07	3.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGF2—coronary artery disease	6.25e-07	3.06e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—coronary artery disease	6.2e-07	3.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK1—coronary artery disease	6.18e-07	3.03e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOS3—coronary artery disease	6.16e-07	3.02e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—coronary artery disease	6.1e-07	2.98e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—coronary artery disease	6.08e-07	2.98e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—coronary artery disease	6.04e-07	2.95e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—coronary artery disease	5.96e-07	2.92e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—VCAN—coronary artery disease	5.95e-07	2.91e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDOA—coronary artery disease	5.91e-07	2.89e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—coronary artery disease	5.89e-07	2.88e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—coronary artery disease	5.87e-07	2.87e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—coronary artery disease	5.86e-07	2.87e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TGFB1—coronary artery disease	5.82e-07	2.85e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—coronary artery disease	5.79e-07	2.83e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—coronary artery disease	5.78e-07	2.83e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—DCN—coronary artery disease	5.74e-07	2.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK1—coronary artery disease	5.71e-07	2.79e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—coronary artery disease	5.68e-07	2.78e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—coronary artery disease	5.61e-07	2.75e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDH2—coronary artery disease	5.58e-07	2.73e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TGFB1—coronary artery disease	5.54e-07	2.71e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—coronary artery disease	5.49e-07	2.69e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—coronary artery disease	5.47e-07	2.68e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LIPC—coronary artery disease	5.44e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HBA1—coronary artery disease	5.44e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3C2A—coronary artery disease	5.44e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2C19—coronary artery disease	5.44e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK1—coronary artery disease	5.43e-07	2.66e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOC3—coronary artery disease	5.4e-07	2.65e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—coronary artery disease	5.4e-07	2.64e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TGFB1—coronary artery disease	5.38e-07	2.63e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LDLR—coronary artery disease	5.37e-07	2.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—coronary artery disease	5.37e-07	2.63e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—coronary artery disease	5.34e-07	2.61e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—coronary artery disease	5.31e-07	2.6e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SLC9A1—coronary artery disease	5.31e-07	2.6e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—coronary artery disease	5.28e-07	2.59e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK1—coronary artery disease	5.27e-07	2.58e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CETP—coronary artery disease	5.25e-07	2.57e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCLC—coronary artery disease	5.25e-07	2.57e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—coronary artery disease	5.23e-07	2.56e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TGFB1—coronary artery disease	5.22e-07	2.55e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—coronary artery disease	5.2e-07	2.55e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—SDC1—coronary artery disease	5.19e-07	2.54e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK1—coronary artery disease	5.12e-07	2.5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—coronary artery disease	5.09e-07	2.49e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—coronary artery disease	5.06e-07	2.48e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—coronary artery disease	4.98e-07	2.44e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—coronary artery disease	4.95e-07	2.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—coronary artery disease	4.95e-07	2.42e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSMA6—coronary artery disease	4.9e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PSMB5—coronary artery disease	4.9e-07	2.4e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—coronary artery disease	4.8e-07	2.35e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CTGF—coronary artery disease	4.79e-07	2.34e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—coronary artery disease	4.75e-07	2.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMGCR—coronary artery disease	4.74e-07	2.32e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GOT2—coronary artery disease	4.74e-07	2.32e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—coronary artery disease	4.71e-07	2.31e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—coronary artery disease	4.58e-07	2.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—coronary artery disease	4.44e-07	2.17e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—coronary artery disease	4.44e-07	2.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—coronary artery disease	4.39e-07	2.15e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—coronary artery disease	4.38e-07	2.15e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PLCB1—coronary artery disease	4.36e-07	2.14e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCA1—coronary artery disease	4.23e-07	2.07e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—coronary artery disease	4.17e-07	2.04e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GGT1—coronary artery disease	4.1e-07	2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GOT1—coronary artery disease	4.1e-07	2e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TGFB1—coronary artery disease	4.08e-07	2e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—coronary artery disease	4.05e-07	1.98e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—coronary artery disease	4.05e-07	1.98e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK1—coronary artery disease	4e-07	1.96e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—coronary artery disease	3.93e-07	1.92e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—coronary artery disease	3.85e-07	1.89e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—coronary artery disease	3.74e-07	1.83e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—coronary artery disease	3.68e-07	1.8e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARGC1A—coronary artery disease	3.64e-07	1.78e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HMOX1—coronary artery disease	3.63e-07	1.78e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—coronary artery disease	3.63e-07	1.78e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAT—coronary artery disease	3.58e-07	1.75e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOB—coronary artery disease	3.47e-07	1.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—coronary artery disease	3.47e-07	1.7e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—coronary artery disease	3.38e-07	1.65e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—LPL—coronary artery disease	3.32e-07	1.62e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GPX1—coronary artery disease	3.24e-07	1.58e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CD36—coronary artery disease	3.15e-07	1.54e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPP2CA—coronary artery disease	3.11e-07	1.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—coronary artery disease	3.07e-07	1.5e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—coronary artery disease	2.99e-07	1.46e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AGT—coronary artery disease	2.84e-07	1.39e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—coronary artery disease	2.83e-07	1.39e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOE—coronary artery disease	2.78e-07	1.36e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA1—coronary artery disease	2.75e-07	1.35e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPARG—coronary artery disease	2.42e-07	1.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POMC—coronary artery disease	2.39e-07	1.17e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—coronary artery disease	2.18e-07	1.07e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NOS3—coronary artery disease	2.08e-07	1.02e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—coronary artery disease	1.91e-07	9.33e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—coronary artery disease	1.17e-07	5.74e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—coronary artery disease	9.58e-08	4.69e-07	CbGpPWpGaD
